Mary A McLean

Sep 12, 2024 | medrxiv.org | Pascal Wodtke |Mary A McLean |Ines Horvat-Menih |Jonathan Birchall

The authors have declared no competing interest. ISRCTN: 13008110PW acknowledges support from the Gates Cambridge Trust (#OPP1144). MM acknowledges support from the Cambridge Experimental Cancer Medicine Centre. This research was further supported by Cancer Research UK (CRUK; C19212/A27150; C19212/A29082), CRUK Cambridge Centre, Wellcome Trust, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).

Sep 12, 2024 | medrxiv.org | Pascal Wodtke |Mary A McLean |Ines Horvat-Menih |Jonathan Birchall

The authors have declared no competing interest. ISRCTN: 13008110PW acknowledges support from the Gates Cambridge Trust (#OPP1144). MM acknowledges support from the Cambridge Experimental Cancer Medicine Centre. This research was further supported by Cancer Research UK (CRUK; C19212/A27150; C19212/A29082), CRUK Cambridge Centre, Wellcome Trust, NIHR Cambridge Biomedical Research Centre (BRC-1215-20014).

Jul 16, 2024 | nature.com | Nikita Sushentsev |Daniel Birtles |Stephanie Ling |Mary A McLean |Jodi Miller |Ian Mills | +2 more

AbstractHyperpolarised magnetic resonance imaging (HP-13C-MRI) has shown promise as a clinical tool for detecting and characterising prostate cancer. Here we use a range of spatially resolved histological techniques to identify the biological mechanisms underpinning differential [1-13C]lactate labelling between benign and malignant prostate, as well as in tumours containing cribriform and non-cribriform Gleason pattern 4 disease.